Improving Protein Production in CHO Cells - Biopharmaceutical protein manufacture can benefit from using chemically defined feeds in CHO cell lines. - BioPharm International

ADVERTISEMENT

Improving Protein Production in CHO Cells
Biopharmaceutical protein manufacture can benefit from using chemically defined feeds in CHO cell lines.


BioPharm International Supplements


Bioreactor Studies


Figure 3
To determine the effects different feeds had on cell numbers and protein expression, a 15-L stir-tank bioreactor (Applikon Biotechnology, Foster City, CA) containing CD CHO medium was inoculated with a different proprietary recombinant IgG CHO cell line at 3 x 105 cells/mL. The pH and dissolved oxygen were set at 6.9 and 50%, respectively, with agitation at 150–175 rpm. The CO2 and oxygen sparge rates were both set at 100 mL/minute. Glucose was added to 6 g/L if the concentration in the media in the bioreactor fell to less than 2 g/L. GS-Max (HyClone, Logan, UT) was fed at 1% of starting volume if the level of glutamate fell to less than 1.5 mM, as occurred in all bioreactors. Four different feed strategies were carried out over 10 days. In one bioreactor (Figure 3), 3% v/v addition of soy hydrolysate was added from a stock of 40 g/L every day for 10 days. In another bioreactor (Figure 4), a 3% v/v solution of chemically defined feed A, (CHO CD EfficientFeed A) was added on days 0–5 followed by addition on days 6–10 of daily supplementation of a 3% v/v solution of chemically defined feed B, (CHO CD EfficientFeed B). The additional two feed strategies determined the effects of higher concentrations of the chemically defined feeds but at fewer time points: 1) a 10% v/v solution of chemically defined feed A was added on days 0 and 3, followed by a 10% v/v solution of chemically defined feed B on days 6, 9, and 2) a 15% v/v solution of feed A was added on day 0 followed by addition of a 15% v/v solution of feed B on day 6. Both total cell counts and protein titers, as determined by ELISA over 13 days, are presented in the results (Figures 3 and 4).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here